Tudor Investment Corp ET AL Purchases New Shares in MiMedx Group, Inc. (NASDAQ:MDXG)

Tudor Investment Corp ET AL purchased a new stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 59,896 shares of the company's stock, valued at approximately $576,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Barclays PLC grew its holdings in shares of MiMedx Group by 163.9% in the third quarter. Barclays PLC now owns 262,449 shares of the company's stock valued at $1,550,000 after acquiring an additional 163,005 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of MiMedx Group by 265.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company's stock worth $1,757,000 after purchasing an additional 215,995 shares during the period. Fiduciary Alliance LLC purchased a new position in shares of MiMedx Group in the 4th quarter worth about $160,000. SG Americas Securities LLC grew its position in MiMedx Group by 79.9% during the fourth quarter. SG Americas Securities LLC now owns 83,385 shares of the company's stock valued at $802,000 after buying an additional 37,031 shares during the period. Finally, Savant Capital LLC purchased a new stake in MiMedx Group during the fourth quarter worth about $100,000. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

MiMedx Group Stock Performance

MDXG stock traded up $0.20 during midday trading on Monday, reaching $7.25. 906,332 shares of the company's stock traded hands, compared to its average volume of 696,287. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The firm has a market capitalization of $1.07 billion, a PE ratio of 13.18 and a beta of 1.85. MiMedx Group, Inc. has a 52 week low of $5.47 and a 52 week high of $10.14. The company has a 50-day moving average price of $7.28 and a two-hundred day moving average price of $8.15.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.06. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The business had revenue of $88.21 million during the quarter, compared to analyst estimates of $86.32 million. As a group, equities analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Insider Transactions at MiMedx Group

In other news, CAO William Frank Iv Hulse sold 81,446 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $7.80, for a total transaction of $635,278.80. Following the completion of the transaction, the chief accounting officer now directly owns 494,774 shares in the company, valued at $3,859,237.20. This trade represents a 14.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Joseph H. Capper bought 200,000 shares of MiMedx Group stock in a transaction on Friday, May 2nd. The stock was acquired at an average cost of $6.34 per share, with a total value of $1,268,000.00. Following the acquisition, the chief executive officer now owns 529,530 shares in the company, valued at approximately $3,357,220.20. This represents a 60.69% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 144,018 shares of company stock worth $1,130,312. Company insiders own 1.30% of the company's stock.

Wall Street Analyst Weigh In

MDXG has been the subject of several research analyst reports. Cantor Fitzgerald restated an "overweight" rating and set a $13.00 price target on shares of MiMedx Group in a research note on Thursday, February 27th. StockNews.com cut MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.